Stockscreener 앱 받기
1.21
4.72%
-0.06
시장 영업 전:
1.12
-0.09
-7.44%
Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - Morningstar
BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell LawsuitBCLI - ACCESS Newswire
BCLI’s Market Whiplash: -50.66% YTD Decline, -17.04% Plunge in 30 Days - investchronicle.com
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting - marketscreener.com
Groundbreaking ALS Treatment Discovery: How Genetics May Predict NurOwn Therapy Success - Stock Titan
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Stem Cell Therapy Market Size, Share & Trends Analysis 2025-2032 | Osiris Therapeutics, Inc., Kolon TissueGene - newstrail.com
Brainstorm Cell Therapeutics adjusts quorum requirement By Investing.com - Investing.com India
Brainstorm Cell Therapeutics adjusts quorum requirement - Investing.com
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - American Banking and Market News
Brainstorm seeks FDA OK to launch NurOwn Phase 3b trial in ALS - ALS News Today
BrainStorm advances ALS therapy with FDA trial submission By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
BrainStorm advances ALS therapy with FDA trial submission - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Nasdaq
Indo-Asian News Service - Indo-Asian News Service (IANS)
BCLI stock touches 52-week low at $1.05 amid sharp annual decline - Investing.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - Insider Monkey
Stacy Lindborg, PhD's Profile Page - Technology Networks
BrainStorm Cell Therapeutics Reports 2024 Financial Results - TipRanks
BrainStorm Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com Canada
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting By Investing.com - Investing.com South Africa
Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Nasdaq
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Monday - Defense World
Brainstorm Cell Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Brainstorm Cell Therapeutics gains extension from Nasdaq - Investing.com
Brainstorm Cell Therapeutics gains extension from Nasdaq By Investing.com - Investing.com India
BrainStorm Cell Therapeutics Granted Compliance Extension from N - GuruFocus.com
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - MarketScreener
BrainStorm Wins Critical Nasdaq Extension: New ALS Study and Strategic Plans Unveiled - Stock Titan
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - The Malaysian Reserve
BrainStorm Cell Therapeutics Sets Major Investor Briefing: CEO, COO, and CMO to Reveal 2024 Performance - Stock Titan
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
5.24%
자본화:
|
볼륨(24시간):